GI Stool Testing Market Revenue to Attain USD 4.76 Bn by 2033

31 Jul 2025

Share :

Table of Content

1. GI Stool Testing Market Revenue and Trends 2025 to 2033 2. 3. Market Overview 4. Segment Outlook 5. Regional Insights 6. GI Stool Testing Market Coverage 7. GI Stool Testing Market Key Players

GI Stool Testing Market Revenue and Trends 2025 to 2033

The global GI stool testing market revenue surpassed USD 3.09 billion in 2025 and is predicted to attain around USD 4.76 billion by 2033, growing at a CAGR of 5.53%. The growth of the market is attributed to the increasing number of cases of gastrointestinal diseases, rising demand for non-invasive diagnostic solutions, and advancements in testing technologies.

Market Overview

The GI stool testing market is experiencing growth due to several factors. The increasing incidence of gastrointestinal conditions like IBS, IBD, colorectal cancer, and infections is driving demand for reliable, non-invasive diagnostic tools. Growing public awareness of gut health and advancements in molecular diagnostics, including the use of stool-based microbiome testing, are also contributing to demand. Emerging technologies such as multiplex PCR, NGS, and AI-powered analysis are improving the accuracy of tests and shortening completion times, attracting clinicians and consumers. The shift toward preventive and personalized medicine further expands the consumer base. Supportive governmental policies, increased healthcare spending, and a growing geriatric population will also support market growth in both developed and developing regions.

Segment Outlook

• By test type, the occult blood test (FOBT, FIT) segment led the market with the largest share in 2024. This is mainly due to the increased demand for colorectal cancer screening. Immunochemical-based FOBT plays a crucial role in colorectal cancer screening, driven by its accuracy and ability to detect hidden blood in stool.
• By technology, the immunoassay segment maintained dominance in the market in 2024, driven by its ability to provide fast and reliable results, which is a major factor increasing its use in clinical settings.
• By application, the colorectal cancer screening segment dominated the market with the largest share in 2024. This is primarily due to the increased prevalence of colorectal cancer. People have become more aware of the early detection of diseases, which has further bolstered the demand for GI stool testing.
• By sample collection method, the hospital/laboratory collection segment dominated the GI stool testing market in 2024 because they operates in a controlled environment and ensures accurate sample processing for reliable results and sample analysis.
• By end-user, the hospitals & clinics segment held the largest share of the market in 2024 because they often experience a high volume of patients undergoing diagnostics. The availability of advanced diagnostic solutions in these settings, along with reimbursement policies for hospital treatments, increases patient footfall in these settings.

Regional Insights

North America sustained dominance in the GI stool testing market in 2024, holding the largest market share. This is mainly due to the increased prevalence of gastrointestinal diseases, well-established healthcare infrastructure, and a high level of awareness regarding early diagnosis. The U.S. is a major player in the market, benefiting from government programs supporting colorectal cancer screening and a greater acceptance of non-invasive tests like Cologuard.

On the other hand, Asia Pacific is expected to experience the fastest growth in the upcoming period, as countries like India and China are expanding their healthcare facilities. The growing awareness of gastrointestinal health further increases the demand for GI stool testing.

GI Stool Testing Market Coverage

Recent Development

• In November 2024, EmeritusDX introduced GI Detect, a comprehensive test utilizing a single stool swab to identify 26 pathogens, including bacteria, viruses, and parasites, delivering results within 24 hours. This innovation enhances the efficiency of diagnosing gastrointestinal disturbances. (Source: https://www.prweb.com)

GI Stool Testing Market Key Players

• Exact Sciences Corporation
• BioFire Diagnostics (bioMérieux)
• QuidelOrtho Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Roche Diagnostics
• Hologic, Inc.
• CerTest Biotec
• Alere Inc. (now part of Abbott)
• Genova Diagnostics
• Diagnostic Solutions Laboratory
• Promega Corporation
• Biomerica, Inc.
• Gastrointestinal Diagnostic Laboratory (GDX)
• Biomerieux SA
• Siemens Healthineers
• MyBioma
• DayTwo
• Seegene Inc.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6499

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344